At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 51 enrolled
Drug / intervention
Pelacarsen (TQJ230) 80 mg s.c. +1 moredrug
Likely dose
Pelacarsen (TQJ230) 80 mg s.c.from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Multicenter Trial Assessing the Reduction of the Rate of Lipoprotein Apheresis After Treatment With Pelacarsen (TQJ230) Compared to Placebo in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease Undergoing Weekly Lipoprotein Apheresis in Germany
In Brief
A Phase 3 clinical trial evaluating Pelacarsen (TQJ230) 80 mg s.c. and Corresponding Placebo for Hyperlipoproteinemia(a). Completed, enrolled 51 participants across 13 sites.
Detailed Summary
Phase III study to test the hypothesis that treatment with pelacarsen (TQJ230) 80 mg Q4W compared to placebo significantly reduces the rate of lipoprotein apheresis in patients with hyperlipoproteinemia (a) and established cardiovascular disease currently undergoing lipoprotein apheresis in Germany on a weekly schedule.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperlipoproteinemia(a)
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedMar 2022
Enrollment StartAug 2022
Primary CompletionJan 2025
TodayJul 2026
First PostedMar 31, 2022
Enrollment StartAug 19, 2022
Primary CompletionJan 28, 2025
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 4.3 years ago
Interventions
Pelacarsen (TQJ230) 80 mg s.c.drug
Pelacarsen (TQJ230) 80 mg s.c. Q4W
Corresponding Placebodrug
Placebo to Pelacarsen